Who Supplies Levothyroxine to India from BRAZIL

Importing finished pharmaceutical formulations containing Levothyroxine into India requires compliance with the Central Drugs Standard Control Organization (CDSCO) regulations. The process involves obtaining an import license in Form 10 from the Directorate General of Foreign Trade (DGFT) and registering the product with CDSCO. The registration process includes submitting Form 40, a Free Sale Certificate, a Certificate of Pharmaceutical Product (COPP), and a Good Manufacturing Practice (GMP) certificate. The timeline for import drug registration can vary, but it typically takes several months to complete all necessary procedures. Specific requirements for Levothyroxine formulations under HS Code 30049099 include providing detailed product information, manufacturing details, and compliance with Indian pharmacopoeia standards.

Imported Levothyroxine formulations must undergo quality testing at CDSCO-approved laboratories. Batch-wise testing is mandatory, and a Certificate of Analysis (CoA) is required for each batch. Stability data demonstrating compliance with International Council for Harmonisation (ICH) Zone IV conditions is necessary. Products must meet the standards set by the Indian Pharmacopoeia. Upon arrival, customs drug inspectors conduct port inspections to verify compliance with these requirements.

Between 2024 and 2026, CDSCO has implemented regulatory updates affecting the import of finished pharmaceutical formulations, including Levothyroxine. The Production Linked Incentive (PLI) scheme has been introduced to encourage domestic manufacturing, potentially impacting the volume of imports. Bilateral agreements between India and Brazil have been established to facilitate pharmaceutical trade, including mutual recognition of Good Manufacturing Practices (GMP). These agreements aim to streamline the import process and ensure product quality.

India imports finished Levothyroxine formulations to meet the demand for patented and branded products, as well as specific dosage forms not produced domestically. The domestic capacity for Levothyroxine formulations is limited, leading to a dependency on imports to fulfill market needs. The market size for Levothyroxine formulations in India is substantial, with a total export market of $77.7 million across 125 exporters to 71 countries.

The import duty structure for Levothyroxine formulations under HS Code 30049099 includes a Basic Customs Duty (BCD) of 10%, an Education Cess of 2%, a Secondary Higher Education Cess of 1%, and a Countervailing Duty (CVD) of 6%. The Social Welfare Surcharge (SWS) is 10%. The Integrated Goods and Services Tax (IGST) is 12%. There are no exemptions or preferential rates for Brazil-origin products. The total landed duty percentage is approximately 17.10%.

India sources Levothyroxine formulations from Brazil due to the availability of patented formulations and specialized dosage forms not produced domestically. Brazil's competitive advantage lies in its adherence to international quality standards and GMP compliance. Other suppliers include China, Germany, and the United States; however, Brazil's share in the Indian market is growing due to these advantages.

India imports Levothyroxine formulations from Brazil due to the availability of patented formulations and specialized dosage forms not produced domestically. Brazil's adherence to international quality standards and GMP compliance ensures the reliability of these products. Specific formulations, such as certain tablet strengths or combination products, are sourced from Brazil to meet the diverse needs of the Indian market.

Compared to other origins like China, the European Union, and the United States, Brazil offers competitive pricing and high-quality Levothyroxine formulations. Brazil's regulatory compliance and GMP adherence provide a level of reliability that is highly valued in the Indian market. While other suppliers may offer similar products, Brazil's unique advantage lies in its consistent product quality and favorable trade relations with India.

Potential risks for Indian importers include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should diversify their supplier base, monitor currency exchange rates, stay updated on regulatory changes, conduct regular quality audits, and maintain buffer stock to manage supply chain disruptions.

1. 1Diversify sourcing by engaging multiple suppliers to reduce dependency on a single source.
2. 2Implement robust inventory management practices to ensure consistent supply and mitigate potential disruptions.
3. 3Establish clear payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP), to manage financial risks.
4. 4Negotiate Minimum Order Quantities (MOQs) that align with demand forecasts to optimize inventory levels.
5. 5Conduct thorough supplier qualification processes, including audits and assessments, to ensure compliance with quality and regulatory standards.

1. 1Obtain a valid Importer Exporter Code (IEC) from the Directorate General of Foreign Trade (DGFT).
2. 2Register the product with CDSCO by submitting Form 40, along with a Free Sale Certificate, COPP, and GMP certificate.
3. 3Apply for an import license in Form 10 from DGFT.
4. 4Ensure compliance with all regulatory requirements as outlined by CDSCO.
5. 5Engage a licensed customs broker to facilitate customs clearance.
6. 6Obtain an advance ruling for HS Code 30049099 to confirm classification and applicable duties.

1. 1Certificate of Analysis (CoA) for each batch.
2. 2Certificate of Pharmaceutical Product (COPP).
3. 3GMP certificate from a recognized authority.
4. 4Drug Master